Vanda Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 51.72 million compared to USD 50.04 million a year ago. Net loss was USD 48.57 million compared to USD 29.49 million a year ago.
Basic loss per share from continuing operations was USD 0.82 compared to USD 0.5 a year ago. Diluted loss per share from continuing operations was USD 0.82 compared to USD 0.5 a year ago.

















